Sequence vs Trimi: Pricing Comparison 2026
A comprehensive pricing comparison between Sequence and Trimi for GLP-1 weight loss treatment. Analyze monthly costs, annual totals, what each provider includes, and which delivers the best clinical value per dollar.
More on GLP-1 Provider Comparisons
Two Different Approaches to GLP-1 Treatment
Sequence and Trimi represent two fundamentally different approaches to GLP-1 weight loss treatment. Sequence is a premium platform that bundles genetic testing, personalized protocols, and a science-forward brand experience into a higher-priced package. Trimi is a value-focused provider that delivers the same core medication with equivalent clinical oversight at a significantly lower price point. Understanding what each approach actually delivers helps you make the right choice for your situation.
Both providers are legitimate, both use compounded medications from FDA-registered pharmacies, and both employ board-certified medical providers. The medication you receive — whether semaglutide or tirzepatide — is pharmacologically identical between the two platforms. The price difference does not reflect a medication quality difference. It reflects a different business model, different supplementary services, and different overhead structures.
Complete Side-by-Side Comparison
| Feature | Sequence | Trimi |
|---|---|---|
| Semaglutide monthly cost | $199–$349/mo | $99/mo |
| Tirzepatide monthly cost | $249–$399/mo | From $149/mo |
| Medication source | FDA-registered compounding | FDA-registered compounding |
| Provider consultations | Included | Included |
| Genetic testing | Yes (select plans) | Not included |
| Flat dose-independent pricing | Varies by plan | Yes |
| Contract required | Yes (3–6 months) | No (month-to-month) |
| Cancellation penalties | May apply | None |
| Shipping | Included | Free |
| Semaglutide 12-month total | $2,388–$4,188 | $1,188 |
| Tirzepatide 12-month total | $2,988–$4,788 | From $1,788 |
| Annual savings with Trimi | — | $1,200–$3,000+ |
The Cost-per-Result Perspective
The most meaningful way to compare Sequence and Trimi is not just total cost but cost per unit of clinical benefit. Since both providers offer the same medication with comparable clinical oversight, the expected clinical outcomes — weight loss, metabolic improvement, appetite reduction — should be similar. This means the cost-per-result is proportional to the total cost, and Trimi delivers approximately the same clinical benefit at 30% to 50% of Sequence's price.
Sequence proponents would argue that genetic testing and personalized protocols may produce incrementally better outcomes for some patients. This is theoretically possible but clinically unproven for GLP-1 therapy specifically. Even if genetic guidance improved average weight loss by 1–2 percentage points — a generous assumption — the cost of achieving that marginal improvement through Sequence's premium would be extremely high on a per-percentage-point basis compared to the base result achievable through standard clinical management.
For patients who have already tried standard GLP-1 therapy and found it insufficiently effective despite appropriate dosing and adherence, exploring Sequence's genetic approach may have merit. For patients starting fresh, the financially prudent approach is to begin with an affordable provider like Trimi, assess your response on standard protocols, and explore premium options only if your clinical response is suboptimal. This strategy minimizes cost while preserving the option to escalate to more comprehensive services if genuinely needed.
Start Lean, Escalate if Needed
Starting with Trimi at $99/month costs $1,188 in year one. If you later decide genetic testing would help, adding it from an independent service costs $100–$300 one-time. Total: approximately $1,500. Sequence year-one cost: $2,400–$4,800. The lean-start approach is significantly cheaper even with added genetic testing.
Who Should Choose Which Provider
Choose Trimi if
You want the most affordable path to effective GLP-1 therapy. You value transparent, predictable pricing. You prefer month-to-month flexibility without contracts. You are confident that standard clinical protocols and responsive provider support will meet your needs. You want to save $1,200 to $3,000 annually without compromising medication quality.
Choose Sequence if
You strongly value pharmacogenomic data and are willing to pay a significant premium for it. Budget is not a primary concern and you can comfortably sustain $200–$400/month for twelve or more months. You have had suboptimal results with standard GLP-1 protocols and want additional diagnostic insight. You value the premium brand experience as part of your treatment journey.
For most patients, the calculus favors Trimi. The medication is identical, the clinical supervision is comparable, and the savings are substantial. The premium Sequence charges funds features that are intellectually interesting but clinically unproven for GLP-1 therapy specifically. Patients who want to explore these features can do so, but they should do so with clear understanding of what the premium buys and what it does not.
Frequently Asked Questions
How much cheaper is Trimi than Sequence?
Trimi is typically $100 to $300 per month cheaper than Sequence for equivalent GLP-1 medications. For semaglutide, Trimi charges $99 per month while Sequence ranges from $199 to $349 per month. Over a twelve-month treatment course, this translates to $1,200 to $3,000 in total savings. The savings are even larger for patients on tirzepatide or at higher dose tiers where Sequence's pricing is at its highest.
Do Sequence and Trimi use the same medication?
Yes, both Sequence and Trimi offer compounded semaglutide and tirzepatide sourced from FDA-registered compounding pharmacies. The active pharmaceutical ingredient is identical — the same molecule producing the same clinical effects. The price difference between the two providers does not reflect a difference in medication quality but rather in supplementary services, platform features, and business model.
Does Sequence's genetic testing justify the higher price?
Sequence's genetic testing provides scientifically legitimate data, but no large-scale clinical trial has demonstrated that genetically guided GLP-1 prescribing produces significantly better weight loss outcomes than standard dose titration protocols. The genetic data may be interesting and informative, but paying $100 to $300 more per month for it over twelve or more months is a significant financial commitment for an unproven clinical advantage. Patients can also obtain pharmacogenomic testing independently at a one-time cost if they are curious.
Which provider has better clinical oversight?
Both Sequence and Trimi provide board-certified medical providers who manage GLP-1 prescribing, dosing, and side effect monitoring. The quality of clinical oversight is comparable between the two platforms. Sequence integrates genetic data into clinical decisions, which is a differentiator, though the impact on treatment outcomes is unproven. Trimi emphasizes responsive provider access and personalized clinical support through direct physician engagement.
Can I try Sequence first and switch to Trimi later?
You can, but be aware of Sequence's contract commitment terms. If Sequence requires a multi-month commitment, switching before the commitment period ends may involve cancellation fees. A more cost-effective approach is to start with Trimi (no contract, month-to-month) and add independent genetic testing if you want that data. This gives you maximum flexibility at the lowest cost.
What does Trimi offer that Sequence does not?
Trimi offers flat, dose-independent pricing that does not change as your medication dose increases — Sequence's pricing may increase with dose. Trimi provides month-to-month flexibility with no contract commitments — Sequence typically requires multi-month contracts. Trimi charges no cancellation fees — Sequence may impose them. And Trimi's transparent pricing means the advertised price is the price you pay, with no hidden fees or surprise charges.
What does Sequence offer that Trimi does not?
Sequence offers pharmacogenomic testing, which provides genetic data about drug metabolism and physiological traits. Sequence also offers a premium technology platform with detailed scientific content and personalized treatment messaging based on genetic results. These features provide additional data and a more premium user experience, though their impact on clinical outcomes has not been established through comparative trials.
Sources & References
- Sequence. Official pricing and program information. 2026.
- STEP 1 trial: semaglutide in adults with overweight or obesity (PubMed).
- SURMOUNT-1 trial: tirzepatide for obesity (PubMed).
- Roden DM, et al. "Pharmacogenomics." The Lancet, 2019;394(10197):521-532.
- FDA guidance on compounding and the FDA.
- Wegovy prescribing information from the FDA.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program. Trimi is a competing provider; this comparison is presented fairly but readers should verify current pricing directly with each provider.